이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genexine 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

CEO

Genexine 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Jungwon Woo	President & Director	2.7yrs	데이터 없음	0.012% ₩ 31.0m
Neil K. Warma	President & Director	2.3yrs	데이터 없음	데이터 없음
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	5.88% ₩ 15.3b
Sung-June Hong	Executive VP	no data	데이터 없음	0.012% ₩ 31.5m
Jongsoo Lee	Senior Manager of IR & PR	no data	데이터 없음	데이터 없음
Hyun Jin Park	EVP of Corporate Development	2.7yrs	데이터 없음	데이터 없음
Jong Sup Park	Chief Medical Officer	5.5yrs	데이터 없음	데이터 없음
Jang Hee Lee	EVP of Operations	2.7yrs	데이터 없음	데이터 없음
Ki Yong Kim	SVP of Bio Research Institute	2.7yrs	데이터 없음	데이터 없음
Chul Jun Hyun	Auditor & Director	2.7yrs	데이터 없음	데이터 없음
Jaehyun Choi	Head of R&D	less than a year	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

경험이 풍부한 관리: A095700 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jungwon Woo	President & Director	2.7yrs	데이터 없음	0.012% ₩ 31.0m
Neil K. Warma	President & Director	2.3yrs	데이터 없음	데이터 없음
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	2.6yrs	데이터 없음	5.88% ₩ 15.3b
Sung-June Hong	Executive VP	2.7yrs	데이터 없음	0.012% ₩ 31.5m
Chul Jun Hyun	Auditor & Director	2.7yrs	데이터 없음	데이터 없음
Young-Jin Kim	Chairman of BOD	2.7yrs	데이터 없음	데이터 없음
Keon Pai Jin	Non-Executive Director	2.7yrs	데이터 없음	데이터 없음
Mijung Ahn	Member of Scientific Advisory Board	2.7yrs	데이터 없음	데이터 없음
Peter Laivins	Director	2.7yrs	데이터 없음	데이터 없음
Hyeok Jong Lee	Director	2.7yrs	데이터 없음	데이터 없음
Heeseop Shin	Member of Scientific Advisory Board	2.7yrs	데이터 없음	데이터 없음
Munseok Gang	Member of Scientific Advisory Board	2.7yrs	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: A095700 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Genexine 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

No independent directors

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

CEO

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령